ArticleBreast cancer research and treatment2011
Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes.
Article in Breast cancer research and treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Genome-wide screen identifies a novel prognostic signature for breast cancer survival.Oncotarget · 2017Pooled it
- Comprehensive analysis of non-synonymous single-nucleotide polymorphism of human TSC1 and TSC2 genes: An in silico approach.PloS one · 2026Article
- Cholesterol-conjugated miR-29b induces fetal haemoglobin expression via γ-globin promoter demethylation in the Townes mouse model for sickle cell anaemia.British journal of haematology · 2025Article
- Lower cytoplasmic expression of DDIT4 is associated with poor prognosis in gastric cancer patients.Discover oncology · 2025Article
- TSC1 deficiency drives immune evasion in colorectal cancer via mTORC1-mediated dysregulation of PD-L1 sialylation.Frontiers in immunology · 2025Article
- mTOR pathway candidate genes and obesity interaction on breast cancer risk in black women from the Women's Circle of Health Study.Cancer causes & control : CCC · 2023Article
- mTOR pathway candidate genes and physical activity interaction on breast cancer risk in black women from the women's circle of health study.Breast cancer research and treatment · 2023Article
- The role of TSC2 in breast cancer: a literature review.Frontiers in oncology · 2023Review
- Establishing a genomic radiation-age association for space exploration supplements lung disease differentiation.Frontiers in public health · 2023Article
- mTOR pathway gene expression in association with race and clinicopathological characteristics in Black and White breast cancer patients.Discover oncology · 2022Article
- Epigenetic Determinants of Racial Disparity in Breast Cancer: Looking beyond Genetic Alterations.Cancers · 2022Review
- Role of TSC1 in physiology and diseases.Molecular and cellular biochemistry · 2021Review
- Article
- miRTissue: a web application for the analysis of miRNA-target interactions in human tissues.BMC bioinformatics · 2018Article
- Association of breast cancer risk and the mTOR pathway in women of African ancestry in 'The Root' Consortium.Carcinogenesis · 2017Article
- Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women.Cancer causes & control : CCC · 2016Article
- Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects.International journal of molecular sciences · 2016Review
- Genetic variants in the mTOR pathway and breast cancer risk in African American women.Carcinogenesis · 2016Article
- Fatty acid extract from CLA-enriched egg yolks can mediate transcriptome reprogramming of MCF-7 cancer cells to prevent their growth and proliferation.Genes & nutrition · 2016Article
- Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
TSC1 acts coordinately with TSC2 in a complex to inhibit mTOR, an emerging therapeutic target and known promoter of cell growth and cell cycle progression. Perturbation of the mTOR pathway, through abnormal expression or function of pathway genes, could lead to tumorigenesis. TSC1 and TSC2 expression is reduced in invasive breast cancer as compared with normal mammary epithelium. Because single nucleotide polymorphisms (SNPs) in regulatory genes have been implicated in risk and age at diagnosis of breast cancers, systematic SNP association studies were performed on TSC1 and TSC2 SNPs for their associations with clinical features of breast cancer. TSC1 and TSC2 haplotypes were constructed from genotyping of multiple loci in both genes in healthy volunteers. SNPs were selected for further study using a bioinformatics approach based on SNP associations with drug response in NCI-60 cell lines and evidence of selection bias based on haplotype frequencies. Genotyping for five TSC1 and one TSC2 loci were performed on genomic DNA from 1,137 women with breast cancer. This study found that for TSC1 rs7874234, TT variant carriers had a 9-year later age at diagnosis of estrogen receptor positive (ER+), but not ER-, ductal carcinomas (P = 0.0049). No other SNP locus showed an association with age at diagnosis, nor any other breast cancer phenotype. TSC1 rs7874234 is hypothesized to be functional in ER+ breast cancer because the T allele, but not the C allele, may create an estrogen receptor element (ERE) site, resulting in increased TSC1 transcription and subsequent inhibition of mTOR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.